|
Oct 10
|
InnoCare’s Phase II psoriasis therapy trial meets primary endpoint
|
|
Oct 9
|
InnoCare Announces Phase II Study Results of TYK2 Inhibitor ICP-488 Meet Primary Endpoint in Psoriasis Patients
|
|
Jan 16
|
InnoCare Announces Clearance of Clinical Trial of BCL2 Inhibitor ICP-248 by U.S. FDA
|